On August 7, 2026, Australian precision oncology networks updated recommendations for targeting tyrosine kinase alterations in rare gastrointestinal cancers. For patients with FGFR2-positive cholangiocarcinoma, sourcing targeted options like Lucinfig (Infigratinib) 25mg Capsules 21's is a crucial step for dose adjustment and treatment continuity.

At Onco Medicine, we cooperate with international supply corridors to deliver authentic, batch-verified targeted therapies to clinics and patients across Australia under strict regulatory guidelines.

Targeted FGFR Inhibition in Cholangiocarcinoma

Bile duct cancer harboring FGFR2 fusions is highly aggressive. Targeted kinase inhibitors like Infigratinib offer a focused mechanism of action:

• Selective Kinase Blockade: Selectively binds to Fibroblast Growth Factor Receptor 2 (FGFR2), halting the signaling cascades that cause tumor proliferation.
• Dose Customization: The 25mg strength allows oncologists to customize dosing regimens for patients requiring dose reductions due to adverse events like hyperphosphatemia.
• Administration Steps: Taken orally once daily on an empty stomach for 21 consecutive days followed by 7 days off, completing a 28-day cycle.

TGA Personal Importation Scheme Compliance

Australian patients can legally import Lucinfig under TGA regulations with a valid oncologist prescription. Onco Medicine manages all customs compliance requirements, ensuring that each shipment contains the commercial invoice, oncologist prescription, and manufacturer Certificate of Analysis (COA) to guarantee a secure, delay-free delivery to your clinical facility in Australia.